Analysis10k / Blog
EN한국어ES
Reverse DCF · ABBV

What ABBV's Stock Price Is Really Betting On

The short answer

At today's price, AbbVie's stock is pricing in roughly 10.7% annual free-cash-flow growth for the next ten years, at a 9% discount rate. Over the past five years, the company's actual free cash flow shrank 5.1% a year on average.

The conclusion

At its current price, ABBV implies ~10.7% annual free-cash-flow growth for the next 10 years, discounted at 9%.

AbbVie's actual free cash flow shrank 5.1% a year on average over the past five years.

Verdict: expectations far above track record The market is pricing in a sharp reversal from AbbVie's recent cash-flow trend — not a continuation of it. That gap isn't necessarily a red flag on its own; it means the price is betting the Skyrizi/Rinvoq growth story and the company's acquisition strategy will turn free cash flow around, rather than betting on the last five years repeating.

Required growth vs. historical growth

Market's ask (WACC 9%)
10.7%
5-yr revenue CAGR (actual)
2.1%
5-yr FCF CAGR (actual)
-5.1%

Required growth from the reverse DCF below. Historical CAGRs calculated from 10-K FY2021–FY2025 (revenue $56.20B → $61.16B; FCF $21.99B → $17.82B).

Sensitivity: what if the discount rate moves?

Required growth by discount rate: 8% gives 8.27%, 9% gives 10.67%, 10% gives 12.87%, 12% gives 16.87%8.27%8%10.67%9% (base)12.87%10%16.87%12%
Discount rate (bottom) vs. the growth the price then requires.
Required 10-year FCF growth by discount rate (WACC)
WACCRequired annual growth
8%8.27%
9% (base case)10.67%
10%12.87%
12%16.87%

Even at the most conservative discount rate tested (8%), the market still requires at least 8% annual FCF growth — well above anything AbbVie has delivered on this measure over the past five years.

What would move this number

  • Using a 3-year average FCF ($19.24B) instead of the trailing-twelve-month figure ($18.21B) lowers the required growth rate slightly, from 10.67% to 9.94% at a 9% discount rate — the conclusion doesn't change.
  • Updating net debt to reflect the Aliada Therapeutics acquisition (completed September 2026, funded partly with new debt) would likely push the required growth rate higher than shown here — that acquisition's financing isn't yet reflected in this calculation.
  • Lowering the terminal growth rate from 2.5% to 2.0% raises the required growth rate by roughly 0.2–0.3 percentage points.

Show your work

Five inputs, sources, model assumptions, and the calculation
  • Share price$264.34 — stockanalysis.com, Sept. 25, 2026 close
  • Diluted shares outstanding1.771B — 10-Q, Q2 FY2026 (quarter ended June 30, 2026), weighted-average diluted shares
  • Market cap$468.1B — price × diluted shares
  • Trailing-twelve-month FCF$18.21B — FY2025 operating cash flow $19.03B minus H1 2025's $6.79B, plus H1 2026's $7.27B, giving TTM operating cash flow of $19.51B, less TTM capex of $1.30B. Source: 10-K FY2025, p.55; 10-Q Q2 FY2026 and Q2 FY2025
  • Net debt$64.25B — total debt $70.82B (short-term borrowings $0 + current portion of long-term debt $8.34B + long-term debt $62.48B) minus cash $6.57B, as of June 30, 2026. Source: 10-Q Q2 FY2026
  • Discount rate (WACC)9% base case (8% / 10% / 12% tested); large stable pharmaceutical classification

FCF normalization check: the trailing-twelve-month figure of $18.21B is 5.3% below the 2023–2025 three-year average of $19.24B, well inside our ±40% threshold, so no adjustment was needed — the TTM figure was used as-is.

Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter. We solve by bisection for the value of g that makes the present value of those cash flows equal today's enterprise value.

ComponentValue
Market cap$468.1B
Net debt$64.25B
Target enterprise value~$532B

EV = Σ(t=1..10) FCF₀×(1+g)ᵗ/(1+WACC)ᵗ + [FCF₀×(1+g)¹⁰×1.025/(WACC−0.025)]/(1+WACC)¹⁰, solved for g by bisection.

The fine print

This number is a starting point, not an answer
  • Change the discount rate, the projection window, the terminal growth rate, or how FCF is normalized, and the answer moves.
  • A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
  • Whether 10.7% annual FCF growth is realistic depends on whether Skyrizi and Rinvoq keep growing, whether IRA price controls bite harder, and whether R&D and acquisition spending keeps weighing on cash flow — not on the math itself.
  • Any investment decision, and its outcome, is your own responsibility.
Built from AbbVie's 10-K (FY2021–FY2025) and 10-Q filings (Q2 FY2025, Q2 FY2026), plus a web search for the current share price (Sept. 25, 2026 close). This tells you where to dig deeper — it is not a buy or sell signal.

How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.

Frequently asked questions

What growth rate does ABBV's stock price assume?

At its current price, AbbVie is pricing in roughly 10.7% annual free-cash-flow growth for the next ten years, discounted at a 9% rate.

How does that compare to AbbVie's actual growth?

AbbVie's free cash flow actually shrank at a 5.1% annual rate over the past five years, while revenue grew just 2.1% a year — both well below the roughly 10.7% annual free-cash-flow growth the current price requires.

What share price was used for this analysis?

This analysis used $264.34, AbbVie's closing price on Sept. 25, 2026.